DOI:
10.1055/s-00000069
Seminars in Liver Disease
LinksClose Window
References
Inventiva's lanifibranor meets the primary and key secondary endpoints in the Phase IIb NATIVE clinical trial in non-alcoholic steatohepatitis (NASH).
Accessed on July 14, 2021 at:
https://www.globenewswire.com/news-release/2020/06/15/2048284/0/en/Inventiva-s-lanifibranor-meets-the-primary-and-key-secondary-endpoints-in-the-Phase-IIb-NATIVE-clinical-trial-in-non-alcoholic-steatohepatitis-NASH.html
Search in:
We do not assume any responsibility for the contents of the web pages of other providers.